Impilo has launched Immedica Pharma – a pan-European specialty pharma commercialization and distribution platform. Immedica's plan is to quickly establish a fast-growing EUR 100m+ leading pan-European niche specialty pharma portfolio composed of partner products as well as proprietary products rights – and spanning from pre-approval stage through peak sales. This will be achieved through world-class launch, commercialization, and distribution capabilities lead by a management team with a very strong and established track record within niche specialty pharma. ...
...
Recientemente, se firmó una importante adición a la cartera con la compañía Farmacéutica Española PharmaMar, en virtud de la cual Immedica se convierte en el distribuidor exclusivo de su Innovador Medicamento contra el Cáncer Yondelis® en los Países Nórdicos y de Europa Central y Oriental.
Yondelis es un Tratamiento establecido para Pacientes que sufren de Sarcomas de Tejidos blandos (STB) y Cáncer de Ovario Sensible al Platino.